NCE-1 Intelligence & Market Opportunity

Exkivity

Mobocertinib

Anticancer

Oral Capsule

Approval Date

15-Sep-21

NCE-1 Date

15-Sep-25

NCE Date

15-Sep-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Mobocertinib

Innovator

TAKEDA PHARMS USA

Dosage Form

Oral Capsule

Strength

EQ 40 mg base

Therapeutic Category

Anticancer

Usage

To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.